Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODEO: Prophylactic Haloperidol Guided by Delirium Risk Model
2017-001260-37Phase 4Active
- Sponsor
- Zuyderland
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of haloperidol in delirium, sponsored by Zuyderland. Primary endpoint: Delirium incidence within five days after surgery. Started May 2017; status: active.
02
Drugs
haloperidol
03
Conditions
delirium
Beyond the preview
Go deeper on 2017-001260-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001260-37.